Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sanofi loses German...

    Sanofi loses German patent case against Amgen over cholesterol drug Praluent

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-09T09:30:18+05:30  |  Updated On 16 Aug 2021 1:05 PM IST

    In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special license that would have protected its Praluent business.


    KARLSRUHE: Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent.


    In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special license that would have protected its Praluent business.


    Officials at Sanofi did not have an immediate comment.


    Amgen had initially sued Sanofi in Germany as part of a legal campaign in various jurisdictions, claiming the French group had violated its patent on Repatha.


    Read Also: Sanofi, Regeneron gets USFDA approval for cholesterol drug Praluent

    Both drugs belong to a class of PCSK9 inhibitors, used against persistently high cholesterol levels in the blood, and aimed at the millions of people who don't benefit from statins such as Pfizer Inc's Lipitor.


    With Amgen's challenge ongoing, Sanofi opened a new legal front and petitioned the German patent court to be granted a license to use Amgen's patent to secure Praluent's continued market presence in Germany, Europe's largest drug market.


    Read Also: Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha

    After its bid was rejected by the patent court in September, Sanofi turned to the higher court but the case was turned down again on Tuesday.


    Praluent will, however, remain on the German market as long as Amgen's legal challenge against the drug's patent continues.


    A U.S. jury in February confirmed the validity of Amgen's patents on Repatha, rejecting a challenge by Sanofi and its partner Regeneron Pharmaceuticals Inc in the protracted dispute.

    Amgencholesterol drugdrug Praluentdrug RepathaGerman patent caseGermanyinhibitorsKARLSRUHEPCSK9 inhibitorsPfizerPfizer Incs LipitorPraluentprotracted disputeRegeneronRegeneron PharmaceuticalsRepatha®Sanofi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok